1.06.09
|
MADEIRA THERAPEUTICS TO PRESENT AT THE BIOTECH SHOWCASE 2009 IN SAN FRANCISCO(January 6, 2009; Leawood, KS) – Madeira Therapeutics announced today that Peter Joiner, Madeira president and chief executive officer, will present an overview of the company at the 2009 Biotech Showcase on January 14, 2009, at 2:45 p.m. Pacific (5:45 p.m. Eastern) time from the Marines’Memorial Club and Hotelin San Francisco, Room A. Madeira Therapeutics currently has two programs in development: MT-001, the first ever liquid preparation of a statin for children and the elderly, and MT-003, a liquid preparation of an analgesic for the treatment of acute pain. About Madeira Therapeutics Madeira Therapeutics, LLC, is a privately held, specialty pharmaceutical company focused on providing safe and effective medicine to pediatric and geriatric patients, parents and the healthcare professionals that serve them. The Madeira strategy focuses on reformulating adult drugs for better dosage control in children. Madeira utilizes the FDA’s 505(b)(2) approval method, which relies in part on the regulatory agency’s findings for a drug previously approved for adults, thereby shortcutting IND approval by years and saving tens of millions of dollars in development costs. The company’s lead program, MT-001, is the first ever liquid preparation of a statin developed for the geriatric and pediatric population. The company’s second product is MT-003 for acute pain relief. For more information, please visit http://www.madeiratherapeutics.com. About the Biotech Showcase The Biotech Showcase provides biotechnology companies, investors and pharmaceutical executives an opportunity to meet in one place during the course of the largest annual healthcare investor conference, which attracts investors and biopharmaceutical executives from around the world. It will take place in a facility that is conveniently located two blocks from the Westin. For more information and registration, please visit http://www.ebdgroup.com/tbs/. |
